EQS-News: Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPO